RCKT

RCKT

Rocket Pharmaceuticals Inc. Common Stock

$3.070+0.000 (0.000%)

リアルタイム価格

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$3.070

高値

$3.070

安値

$3.070

出来高

3.11M

企業ファンダメンタルズ

取引統計

関連ニュース

Analyst Upgrades

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $34 to $11.

もっと見る
Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

もっと見る
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

もっと見る
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Greg Harrison maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $32 to $9.

もっと見る
B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9
Analyst Upgrades

BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8

BMO Capital analyst Kostas Biliouris maintains Rocket Pharmaceuticals with a Outperform and lowers the price target from $30 to $8.

もっと見る
BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8
Analyst Upgrades

Scotiabank Maintains Sector Outperform on Rocket Pharmaceuticals, Lowers Price Target to $19

Scotiabank analyst Greg Harrison maintains Rocket Pharmaceuticals with a Sector Outperform and lowers the price target from $51 to $19.

Analyst Upgrades

Leerink Partners Downgrades Rocket Pharmaceuticals to Market Perform, Lowers Price Target to $8

Leerink Partners analyst Mani Foroohar downgrades Rocket Pharmaceuticals from Outperform to Market Perform and lowers the price target from $37 to $8.